DTIL — Precision Biosciences Balance Sheet
0.000.00%
- $81.33m
- $41.44m
- $68.70m
Annual balance sheet for Precision Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 89.8 | 144 | 190 | 117 | 86.3 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 10 | 0.488 | 0.72 | 12.8 | 1.7 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 106 | 162 | 199 | 136 | 95 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 41.5 | 29.3 | 23.2 | 14.6 | 10.2 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 150 | 211 | 238 | 160 | 136 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 42.8 | 36 | 59.7 | 50 | 15 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 106 | 120 | 178 | 141 | 80 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 44.4 | 91.2 | 60.4 | 18.9 | 56.4 |
| Total Liabilities & Shareholders' Equity | 150 | 211 | 238 | 160 | 136 |
| Total Common Shares Outstanding |